Inicio
Publicaciones Oncología
| Title | Authors/Publication Reference |
|---|---|
| Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. | Tannock IF, et al./ N Engl J Med. 2004;351(15):1502-12. |
| Phase II study with the combination of capecitabine (C) and vinorelbine i(V) n metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes | L. Estevez et al. / ASCO-2004 |
| Phase II study of capecitabine a (C) in combination with docetaxel (D) as neoadjuvant treatment in patients with locally advanced breast cancer (IIIA and IIIB stage) | M. Bellet et al./ ASCO-2004 |
| Phase II study with the combination of capecitabine (C) and vinorelbine i(V) n metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes | L. Estevez et al./ ESMO-2004 |
| Phase II study of capecitabine a (C) in combination with docetaxel (D) as neoadjuvant treatment in patients with locally advanced breast cancer (IIIA and IIIB stage) | M. Bellet et al./ ESMO-2004 |
| Phase II study of capecitabine (C) in combination with docetaxel (D) as neoadjuvant treatment in patients with locally advanced breast cancer (IIIA and IIIB stage). Correlation between clinico-pathological response and fluoropyrimidine-enzyme profile. Early results | M. Bellet et al./ ASCO-2005 |
| Docetaxel followed by capecitabine as first-line chemotherapy in metastatic breast cancer patients: preliminary results | Dr. Bayo et al./ ASCO-2005 |
| Induction (I) or consolidation (C) chemotherapy with docetaxel (D) and gemcitabine (G) plus concomitant chemoradiotherapy (CT/TRT) with docetaxel and carboplatin (Cb) for unresectable stage III non-small cell lung cancer (NSCLC) patients (p). Initial report of the randomized phase II trail SLCG 0008 | P. Garrido & GECP/ ASCO-2005 |
| Phase II/III Trial Induction Chemotherapy (ICT) with Cisplatin/5-Fluoruracil (PF) vs. Docetaxel (T) plus PF (TPF) followed by chemoradiotherapy (CRT) vs. CRT for Unresectable Locally Advanced Head and Neck Cancer(LAHNC) | R. Hitt & TTCC/ ASCO-2005 |
| Toxicity and health-related quality of life (HRQoL) in node negative breast cancer (BC) patients (pts)receiving adjuvant treatment with TAC (docetaxel, doxorubicin, cyclophosphamide) or FAC ( 5-fluoruracil, doxorubicin, cyclophosphamide): Impact of adding prophylactic growth factors ( GF) to TAC. GEICAM Study 9805 | M. Martín & GEICAM/ ASCO-2005 |
| Pharmacogenetic study in patients (pt) with metastatic breast (BC) and colorectal cancer (CRC) treated with capecitabina (C) | Dr. Alba et al./ ASCO-2005 |
| Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study | Dr. Sastre et al./ JClinOncol 2005 May 20; 23 (15): 3545-3551 |
| Irinotecan (CPT-11)-based chemotherapy as induction treatment for advanced colorectal cancer | Dr. Quintela-Fandino/Dra. Grávalos/ Anticancer Drugs. 2005 Jan;16(1):31-8. |
| Guides for adjuvant treatment of colon cancer | Aranda E./ Clin Transl Oncol 2006; 8(2):98-102 |
| A Phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer. | Navarro M./Int J Radiat Oncol Biol Phys 2006 Sep 1; 66(1):201-5 |
| Randomized phase II/III clinical trial of induction chemotherapy (ICT) with either cisplatin/5-fluorouracil (PF) or docetaxel/cisplatin/5-fluorouracil (TPF) followed by chemoradiotherapy (CRT) vs. crt alone for patients (pts) with unresectable locally advanced head and neck cancer (LAHNC). | R. Hitt et al. / ASCO-2006 |
| Estudio asistencial de la combinación de Capecitabina con Carboplatino administrados cada dos semanas en pacientes con cancer de mama metastasico | I. Chacon et al./ ASCO 2006 |
| Docetaxel (T) followed by capecitabine (X) as first-line chemotherapy in patients (pts) with metastatic breast cancer (MBC): Preliminary findings from a phase II study | JL. Bayo et al./ ASCO 2006 |
| Phase II study of capecitabine (X) + docetaxel (T) as neoadjuvant treatment in patients (pts) with locally advanced breast cancer (LABC) including biological correlates. | M. Bellet et al./ ASCO-2006 |
| Phase II study of capecitabine (X) in combination with vinorelbine (N) in patients (pts) with pretreated metastatic breast cancer (MBC). | N. Batista et al/ ASCO-2006 |
| Estudio Fase II randomizado del tratamiento continuo versus tratamiento estandar con capecitabina en pacientes con cáncer de mama metastásico. | M. Martin et al./ ESMO-2006 |
| Randomized phase II trial of radiotherapy with or without Erlotinib in patients with locally advanced or unresectable non small cell lung cancer | E. Martinez/ XI Congreso nacional SEOM, Clin Transl Oncol, vol9, extraordinary 2, Oct 2007: P-141 |
| Randomized phase II trial of radiotherapy with or without Erlotinib in patients with locally advanced or unresectable non small cell lung cancer | E. Martinez/ ASTRO 49th Annual Meeting;2007 |
| Randomized phase II trial of radiotherapy with or without Erlotinib in patients with locally advanced or unresectable non small cell lung cancer | E. Martinez/ 12th WCLC Journal of Thoracic Oncology, vol2, nº8, supplement 4: P3-113 |
| Feasibility and tolerability of the addition of erlotinib to 3D thoracic radiotherapy (RT) in patientes with unresectable NSCLC: a prospective randomized phase II study | E. Martinez et al./ ASCO 2008 |
| Adjuvant Chemotherapy with sequential or concurrent Anthracycline and Docetaxel: Breast International Group 02-98 randomized trial | Francis P/J Natl Cancer Inst 2008;100:121-133 |
| A multicenter phase II study to evaluate the sequential Docetaxel followed by Capecitabine treatment in anthracycline pretreated HER-2 negative patients with metastatic breast cancer | J. Bayo et al./ JClin Transl Oncol 2008 |
| A phase II study of weekly vinorelbine and trastuzumab in patients with HER-2 positive metastatic breast cancer | Bayo-Calero JL et al./ Clin Breast Cancer 2008 Jun; 8(3): 264-8 |
| Randomized study of weekly irinotecan lus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5 fluorouracil/leucovorin (FOLFIRI), as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish cooperative group for the treatment of digestive tumors study | E. Aranda/ Ann. Onc., February 2009; 20: 251 - 257 |
| Final results of a randomized Phase III trial comparing induction chemotherapy (ICT) with cisplatin/5-FU (PF) or docetaxel/cisplatin/5-FU (TPF) followed by chemoradiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC) | Dr Hitt Ret al.& Spanish Head and Neck Cancer Cooperative Group, Spain/ ASCO-2009 |
| Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group | P Garcia-Alfonso et al./ Br J Cancer 2009; 101: 1039–1043. |
Activity of a multitargeted, chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal cell carcinoma: a phase II study (SOGUG-02-06) | Dr Bellmunt/The Lancet Oncology 2010 |
"Phase II, Randomized Study of Concomitant Chemoradiotherapy Followed by Surgery and Adjuvant Capecitabine Plus Oxaliplatin (CAPOX) Compared With | C Fernández-Martos et al/J Clin Oncol 2010 |
| Phase II Study Of Bevacizumab + Oxaliplatin Plus Capecitabine Followed By Bevacizumab + Erlotinib As First-Line Treatment In Metastatic Colorectal Cancer | A Muñoz et al. ASCO 2010; Abstract No: 442 |
| Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single agent (s/a) BEV as maintenance therapy in patients (pts) with metastatic colorectal cancer (mCRC): the MACRO trial | J. Tabernero & Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD), Spain. ASCO 2010; Abstract No: 3501 |
| Phase I study of Sorafenib plus Ifosfamide in patients with advanced soft tissue and bone sarcoma: A Spanish Group for Research on Sarcomas (GEIS) Study | X. Garcia del Muro et al. ASCO 2010; Abstract No: 10024 |
| Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer | J. Feliu et al. Br J Cancer 2010 May 11;102(10):1468-73. |
| Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment | J. Martinez-Trufero et al. Br J Cancer 2010 May 18; 102 (12): 1687 – 1691 |
| Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung Cancer | Cobo M et al. J Clin Oncol 2007; 25;19:2747-2754 |
Activity of a multitargeted, chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal cell carcinoma: a phase II study (SOGUG-02-06) | Dr Bellmunt/The Lancet Oncology 2010;11 (4):350-357 |
Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer | P Garcia-Alfonso et al. British Journal of Cancer (2010) 103, 1524 – 1528 |
| Predictive response factors in an open, non-randomized, phase II study of a combination of bevacizumab and sequential chemotherapy as preoperative treatment in patients with operable HER-2 negative breast cancer | P. Sánchez-Rovira et al. SABCS 2010; Abstract No: 851233 |
| First analysis of the value of Circulating Epithelial Tumor Cells and Circulating Endothelial Cells (CTCs/CECs) in patients with HER-2 negative locally advanced or metastatic breast cancer treated with bevacizumab in combination with paclitaxel and gemcitabine as first line therapy (AVALUZ trial) | L. Manso et al. SABCS 2010; Abstract No:P3-02-11 |
Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer | M. Martin et al. N Engl J Med 2010; 363;23:2200-2210 |
| Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study | A. Abad et al./ Acta Oncol. 2008; 47: 286-292 |
IMAGING: looking for imaging, molecular, and dynamic biomarkers to predict response to bevacizumab-based neoadjuvant therapy. Preliminary findings on tumor hypoxia and proliferation rate assessed by positron emission tomography (PET) | López Vega J. et al. VIII simposium Internacional GEICAM 2011 |
Phase II study of bevacizumab in combination with temozolomide as treatment of patients with recurrent glioblastoma multiforme: preliminary anaysis of toxicity | Sepulveda J et al. European |
Recommendations and Expert Opinion on the Treatment of Locally Advanced Rectal Cancer in Spain |
|
| Recommendations and Expert Opinion on the Adjuvant treatment of Colon Cancer in Spain | Viéitez JM et al. Clin&Transl Oncol. 2011 Nov;13(11):798-804. |
